Century Therapeutics, Inc. $IPSC

What the company doesAI summary of filing

Century Therapeutics is a clinical-stage biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs) for autoimmune diseases, including type 1 diabetes, and cancer. The company's approach uses off-the-shelf, genetically engineered iPSC-derived cells (beta islet cells, T cells, and NK cells) combined with its proprietary Allo-Evasion technology designed to prevent immune rejection and enable repeat dosing. Century does not currently generate revenue from product sales; its lead candidate CNTY-813, a beta islet cell therapy for type 1 diabetes, is in IND-enabling studies with an anticipated IND application submission in 2026, while CNTY-308, a CAR-T cell therapy for B-cell-mediated diseases, and CNTY-101, a CAR-NK cell therapy being tested in a Phase 1/2 investigator-sponsored trial, are in clinical development. [10-K 2026-03-12]

Segments: CNTY-813 (beta islet cell therapy for type 1 diabetes), CNTY-308 (CD19-targeted CAR-T cell therapy for B-cell-mediated autoimmune diseases), CNTY-101 (CD19-targeted CAR-NK cell therapy for B-cell-mediated autoimmune diseases)